Achieve Life Sciences, Inc. (ACHV) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please go ahead. Thank you, Tiffany, and thanks, everyone, for joining us today. On the call, we have John Bences, Chief Executive Officer, Dr. Cindy Jacobs, President and Chief Medical Officer, Jerry Wan, Principal Accounting Officer, and Rick Stewart, Executive Chairman of the Board of Directors. I would like to remind everyone that today's conference call contains forward-looking statements based on current expectations. These statements are only predictions, and actual results may vary materially from those projected. Please refer to Achieve documents filed with the SEC concerning factors that could affect the company, copies of which are available on our website. I would now like to turn the call over to John. Thank you, Jamie. On today's call, we will discuss the exciting progress we have made on the Sinus Center Clean Development Program, including key milestones that we have reached so far in 2021, and provide an update on our second quarter financial results. Let's begin with our phase three ORCA2 trial that is evaluating the efficacy and safety of three milligrams cytosinicline dosed three times daily over a period of six and 12 weeks versus placebo. ORCA2 is being conducted at 17 clinical sites in the United States. And as announced in June, we have reached the key milestone of enrollment completion. As you may recall, the original enrollment target was 750 smokers. However, we allowed additional subjects that were in screening at the time of our cutoff date to participate in the study, resulting in a total of 810 subjects randomized. All subjects have now been assigned to one of three arms to receive either 12 weeks of placebo, 12 weeks of cytosinicline, or a combination of six weeks of cytosinicline followed by six weeks of placebo. Following the 12-week...